Argentina promotes local biosimilar production through Decree 1741/2025 to lower treatment costs and reduce import dependence. The move aims to improve healthcare access but faces challenges in infrastructure and quality control. Experts support the initiative.
The Argentine government has launched a series of measures to promote the local production of biosimilar medicines, aiming to reduce the costs of medical treatments and making them more accessible to the population. Through Decree 1741/2025, the government has established requirements and guidelines for the production and regulation of biosimilars. This initiative seeks not only to lower treatment costs but also to boost the local pharmaceutical industry, creating jobs and fostering autonomy in the supply of essential medicines.
As early as 2021, a report by the Center for Health Technology Assessment (CETSA), affiliated with Isalud University in Buenos Aires, Argentina, highlighted that the costs of highly complex treatments could be reduced if biosimilar drugs were included in the national system [1].
According to ANMAT, biosimilars have great potential to reduce healthcare spending, as they can offer a more economical alternative to innovative drugs while maintaining quality and efficacy. The country's healthcare sector, which faces high costs for specialized treatments, stands to benefit from this measure, improving patient access - particularly for chronic diseases such as cancer, rheumatoid arthritis, and other serious conditions requiring biological therapies.
The measure is part of a broader effort to strengthen Argentina's health sovereignty by promoting local pharmaceutical research and development. The decree also establishes a clear regulatory framework to ensure the safety and quality of biosimilars on the market. By doing so, the government aims to reduce dependence on imports and expand access to high-quality treatments at more affordable prices.
The push for biosimilars has generated optimism among experts and civil society organizations, who viewthe initiative as a step toward modernizing the Argentine healthcare system. However, concerns have been raised about the potential challenges, such as the need for infrastructure upgrades, workforce training, and stringent quality control to ensure that local production meets international standards.
The measures introduced through Decree 1741/2025 represents an important step toward a more inclusive and sustainable healthcare system in the country. This vision aligns with the position of the Argentine Quality Biosimilars Group (GABiC), which includes Amgen, Gobbi Novag, and Sandoz and supports the use of biosimilars as a strategy to promote innovation, sustainability, and broader access to essential medicines [2].
Related articles
Regulatory landscape for biosimilars in Latin America
Optimizing the benefits of biosimilars for society
|
LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Alcanzar los objetivos ASG en el desarrollo farmacéutico Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Alcanzar los objetivos ASG en el desarrollo farmacéutico !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars as a sustainable option for the health system in Argentina [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Jun 10]. Available from: www.gabionline.net/reports/biosimilars-as-a-sustainable-option-for-the-health-system-in-argentina
2. GaBI Online - Generics and Biosimilars Initiative. GABiC proposes the use of biosimilars as strategy for innovation and sustainability [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Jun 10]. Available from: www.gabionline.net/reports/gabic-proposes-the-use-of-biosimilars-as-strategy-for-innovation-and-sustainability
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment